Navigation Links
Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
Date:1/13/2010

Synomics Pharma and BioScience Laboratories, Inc. announced a formal partnership to provide fully integrated topical clinical phase 1 study services for trials in healthy human subjects, providing drug developers with a single source for outsourcing clinical trials.

Wareham, MA (PRWEB) January 13, 2010 -- Synomics Pharma and BioScience Laboratories, Inc. announced a formal partnership to provide fully integrated topical clinical phase 1 study services for trials in healthy human subjects, providing drug developers with a single source for outsourcing clinical trials.

Synomics Pharma’s reliable preclinical and clinical bioanalysis and analytical chemistry services, combined with BioScience Laboratories’ 18 years of experience conducting clinical trials, provides drug developers with a comprehensive outsourcing solution for topical clinical phase 1 study needs in a GCP and GLP compliant environment.

As the need for improved quality of data from clinical trials rises, drug developers are increasingly turning to United States-based contract research organizations (CROs). To ensure regulatory acceptance, pharmaceutical developers are requiring that clinical trials be conducted in strict compliance with the FDA, GCP, and GLP guidelines. For drug developers trying to bring a product to market while adhering to stringent timelines, selecting a CRO capable of conducting the clinical trial on time, on budget, and with resulting data suitable for FDA submission is critical. The partnership between Synomics Pharma and BioScience Laboratories enables an efficient single point of project management, with a full array of bioanalytical and topical clinical trial capabilities.

“Our significant experience in conducting clinical trials, combined with Synomics Pharma’s robust quality system, responsive team, and state-of-the-art bioanalysis techniques, creates an exceptional resource for outsourcing phase 1 clinical trials,” said Daryl Paulson, Ph.D., Chief Executive Officer of BioScience Laboratories.

“Synomics Pharma’s comprehensive quality management system reduces regulatory risk,” said John Pirro, Vice President and Chief Operating Officer of Synomics Pharma. “Our active involvement with the Bioanalytical Quality Standards Initiative (BQSI) for the implementation of ICH Q10 for clinical trials demonstrates our commitment to consistency and quality in clinical bioanalysis. The alliance between Synomics Pharma and BioScience Laboratories produces a versatile topical clinical phase 1 study service offering that will be highly beneficial to the industry.”

A white paper from Synomics Pharma, titled “BioAnalytical Quality Standard Initiative — Implementing ICH Q10 for Clinical Trials”, describes the BQSI, an initiative born out of the industry-wide recognition that neither the US FDA or EMEA regulation nor ICH harmonized guidelines address laboratory analysis in support of clinical trials. To download the white paper, visit http://info.synomicspharma.com/bqsi/.

Synomics Pharmaceutical Services, LLC, a global Contract Research Organization (CRO), specializes in customized preclinical and clinical bioanalytical services, stability studies, and analytical chemistry services for the pharmaceutical industry for the pharmaceutical, personal care, and allied industries. Synomics Pharma, a Smithers Group company, provides a broad portfolio of services in support of drug development and production, and its FDA-inspected quality management system is globally recognized by authorities as an industry benchmark. Smithers Group member company, SP Formulations, provides drug formulation development services in a variety of pharmaceutical dosage forms including parenterals, liquids, and semi-solids.

BioScience Laboratories, Inc. was founded in 1991 in Bozeman, MT, to provide antimicrobial product testing and result interpretation grounded in science. Today, BioScience Laboratories offers a variety of state-of-the-art laboratory services and guidance regarding federal regulatory agency requirements for the healthcare, pharmaceutical, personal care and consumer products markets.

###

Read the full story at http://www.prweb.com/releases/2010/01/prweb3439734.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
2. Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009
3. Keenan Offers New Pharmacy Discount Card Program with No Eligibility Requirements and No Cost to User
4. Penn Pharma Invests In World-Class Inventory Management System
5. Seven More Biopharmaceutical Research Companies Join PhRMA
6. CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccines in 8 New States
7. PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management
8. Pharmacists improve care of diabetics while cutting costs, UB research shows
9. 5,000 Web Sites Selling Prescription Drugs Outside of Pharmacy Laws and Practice Standards
10. Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans
11. CVS/pharmacy and MinuteClinic Now Providing H1N1 Vaccinations in Arizona
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 
(Date:2/21/2017)... Doylestown, Pa. (PRWEB) , ... ... ... leading provider of technology-enabled clinical trial solutions, today announced the further expansion ... types of applications they can leverage as part of Bioclinica’s extensive and ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article ... weight loss. It found that the treatments have led to significant improvements in weight ... to unassisted efforts. It also noted very few problematic results relating to the treatment. ...
(Date:2/20/2017)... ... February 21, 2017 , ... Nancy Johnston Toll marks her debut ... Getting Over the Bump in the Road ” (published by Xlibris). Inspired from her ... cope with the ups and downs experienced by anyone going through cancer treatment and ...
(Date:2/20/2017)... ... February 20, 2017 , ... Researchers at the University of ... well as a marker that may predict response to a particular class of drugs, ... of cancer as well. The new findings were published in Proceedings of the National ...
(Date:2/20/2017)... ... 2017 , ... Best Doctors® and IBM today announced that ... that want to help members of their workforce battling cancer. Through the Best ... suite of oncology offerings for insights on cancer treatment options, ranging from standard ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Lexmark International, ... solution that connects Lexmark multifunction printers (MFPs) to EDCO ... leading scanning and indexing software solutions for medical records. ... use a Lexmark MFP at the point of care ... facilities reach HIMSS Stage 7 through state-of-the-art ...
(Date:2/21/2017)... IDAHO FALLS, Idaho , Feb. 21, 2017 /PRNewswire/ ... is has completed a private placement with certain investors ... preferred stock of the Company, Series C Convertible Redeemable ... Stock accrues dividends at an annual rate of 6% ... share.  The Company plans to use the proceeds for ...
(Date:2/21/2017)... SAN JOSE, Calif. , Feb. 21, 2017 ... announced that its Cadence ® Tensilica ® Fusion ... HaLow ™ MAC IP offering. The licensable IP targets ... smart city and industrial applications. M2B leveraged the Fusion F1 ... to run value-added applications like voice trigger, audio identification and ...
Breaking Medicine Technology: